Basulaiman, Bassam
Awan, Arif Ali
Fergusson, Dean
Vandermeer, Lisa
Arnaout, Angel
Hilton, John
Hutton, Brian
Joy, Anil Abraham
Robinson, Andrew
Califaretti, Nadia
Stober, Carol
Sienkiewicz, Marta
Thavorn, Kednapa
Clemons, Mark http://orcid.org/0000-0002-0738-2713
Funding for this research was provided by:
Cancer Care Ontario (CPQI grant 2017, 2018)
Canadian Institutes of Health Research (Strategies for Patient-Oriented Research)
Canadian Cancer Society Research Institute (ILIAD study)
Article History
Received: 24 April 2019
Accepted: 6 May 2019
First Online: 24 May 2019
Compliance with ethical standards
:
: Dr. Awan reports participating in the Novartis Canada Advisory Board on the use of Ribociclib. Dr. Hutton reports personal fees from Cornerstone Research, outside the submitted work. The remaining authors declare that they have no conflicts of interest to disclose (Basulaiman, Fergusson, Vandermeer, Arnaout, Hilton, Joy, Robinson, Califaretti, Stober, Sienkiewicz, Thavorn, and Clemons).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.